Shinwa Express Vol.111 for Application of sitagliptin using ULTRON ES-OVM.

 

is an oral hypoglycemic drug and one of the DPP-4 inhibitors. As compared with
the conventional oral hypoglycemic drugs, it is less likely to occur hypoglycemia because it
decreases the blood glucose level by increasing the insulin secretion when the blood glucose
level is higher and an antihyperglycemic effect is inhibited when the blood glucose level
reaches normal range. Shown below is a reversed-phase analysis of sitagliptin performed
using the ULTRON ES-OVM.